Concord Biotech

Advanced Manufacturing And CDMO Momentum Will Unlock Global Potential

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

19 Feb 25

Updated

03 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-35.1%

7D

-0.6%

Loading

1Y

-35.1%

7D

-0.6%

You can edit this narrative until Dec 4 7:05 AM. Then, changes will post as Updates.

Author's Valuation

₹1.74k18.9% undervalued

AnalystConsensusTarget Fair Value

Shared on 03 Dec 25

CONCORDBIO: Solar Investment And Strong Margins Will Drive Future Upside

Analysts have maintained their price target on Concord Biotech at ₹1,736.67, reflecting unchanged assumptions on discount rate, revenue growth, profit margin, and future valuation multiples while reiterating confidence in the existing outlook. What's in the News The board has approved an investment of up to INR 100 million in a captive hybrid solar power project for the Limbasi plant, supporting long term energy cost management and sustainability goals (company filing).

Shared on 19 Nov 25

Fair value Decreased 5.62%

CONCORDBIO: Revenue And Profit Margins Are Expected To Drive Stronger Performance

Analysts have lowered their fair value estimate for Concord Biotech from ₹1,840 to approximately ₹1,737. This revision reflects expectations for improved revenue growth and profit margins, partially offset by a higher discount rate and lower projected future P/E multiples.

Shared on 05 Sep 25

With no meaningful changes in Concord Biotech’s net profit margin or future P/E, the consensus analyst price target remains steady at ₹1840. What's in the News Announced annual dividend of INR 10.70 per share, payable in October 2025.

Shared on 01 May 25

Fair value Decreased 12%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Decreased 1.98%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

AnalystConsensusTarget Fair Value

₹1.74k

18.9% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

20.64%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹7.18b

Earnings '28

x

37.43x

PE Ratio '28

=

₹268.89b

Market Cap '28

₹268.89b

Market Cap '28

/

108.08m

No. shares '28

=

₹2.49k

Share Price '28

₹2.49k Share Price '28

Discounted to 2025 @ 12.76% p.a.

=

₹1.74k

Fair Value '25